Stayble Therapeutics AB (publ) (STABL.ST)
SEK 0.46
(-3.75%)
SEK 0.46
(-3.75%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 21.7 Million SEK | 13.35% |
| 2022 | 19.14 Million SEK | -56.12% |
| 2021 | 43.63 Million SEK | 142.48% |
| 2020 | 17.99 Million SEK | 85.17% |
| 2019 | 9.71 Million SEK | 7.95% |
| 2018 | 9 Million SEK | -4.81% |
| 2017 | 9.45 Million SEK | -22.22% |
| 2016 | 12.16 Million SEK | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 15.78 Million SEK | 7.14% |
| 2024 Q1 | 14.72 Million SEK | -32.14% |
| 2023 FY | 21.7 Million SEK | 13.35% |
| 2023 Q4 | 21.7 Million SEK | -25.49% |
| 2023 Q2 | 34.03 Million SEK | 110.59% |
| 2023 Q1 | 16.16 Million SEK | -15.6% |
| 2023 Q3 | 29.12 Million SEK | -14.41% |
| 2022 Q2 | 30.39 Million SEK | -24.0% |
| 2022 FY | 19.14 Million SEK | -56.12% |
| 2022 Q4 | 19.14 Million SEK | -19.22% |
| 2022 Q3 | 23.7 Million SEK | -22.02% |
| 2022 Q1 | 39.99 Million SEK | -8.35% |
| 2021 Q1 | 52.24 Million SEK | 190.29% |
| 2021 FY | 43.63 Million SEK | 142.48% |
| 2021 Q3 | 47.29 Million SEK | -3.31% |
| 2021 Q4 | 43.63 Million SEK | -7.73% |
| 2021 Q2 | 48.91 Million SEK | -6.37% |
| 2020 Q2 | 22.63 Million SEK | -24.13% |
| 2020 Q1 | 29.83 Million SEK | 206.92% |
| 2020 Q4 | 17.99 Million SEK | -9.73% |
| 2020 FY | 17.99 Million SEK | 85.17% |
| 2020 Q3 | 19.93 Million SEK | -11.91% |
| 2019 FY | 9.71 Million SEK | 7.95% |
| 2019 Q4 | 9.71 Million SEK | 64.64% |
| 2019 Q1 | - SEK | -100.0% |
| 2019 Q3 | 5.9 Million SEK | 0.0% |
| 2018 Q4 | 9 Million SEK | 0.0% |
| 2018 FY | 9 Million SEK | -4.81% |
| 2017 FY | 9.45 Million SEK | -22.22% |
| 2016 FY | 12.16 Million SEK | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| 2cureX AB (publ) | 16.62 Million SEK | -30.544% |
| Abliva AB (publ) | 87.49 Million SEK | 75.196% |
| Ascelia Pharma AB (publ) | 87.07 Million SEK | 75.075% |
| AcouSort AB (publ) | 34.51 Million SEK | 37.117% |
| Active Biotech AB (publ) | 44 Million SEK | 50.675% |
| Alzinova AB (publ) | 123.18 Million SEK | 82.382% |
| Amniotics AB (publ) | 26.08 Million SEK | 16.803% |
| Annexin Pharmaceuticals AB (publ) | 26.76 Million SEK | 18.907% |
| Aptahem AB (publ) | 63.02 Million SEK | 65.565% |
| Asarina Pharma AB (publ) | 6.07 Million SEK | -257.131% |
| Alligator Bioscience AB (publ) | 118.45 Million SEK | 81.678% |
| BioInvent International AB (publ) | 1.4 Billion SEK | 98.45% |
| BioArctic AB (publ) | 1.18 Billion SEK | 98.17% |
| Biosergen AB | 7.2 Million SEK | -201.387% |
| Biovica International AB (publ) | 131.4 Million SEK | 83.484% |
| Bio-Works Technologies AB (publ) | 62.15 Million SEK | 65.081% |
| Calliditas Therapeutics AB (publ) | 1.9 Billion SEK | 98.858% |
| Camurus AB (publ) | 1.9 Billion SEK | 98.862% |
| Cantargia AB (publ) | 223.71 Million SEK | 90.299% |
| Corline Biomedical AB | 100.1 Million SEK | 78.32% |
| Scandinavian ChemoTech AB (publ) | 14.86 Million SEK | -45.961% |
| CombiGene AB (publ) | 120.61 Million SEK | 82.006% |
| Cyxone AB (publ) | 43.65 Million SEK | 50.285% |
| Diagonal Bio AB (publ) | 28.5 Million SEK | 23.871% |
| Diamyd Medical AB (publ) | 217.03 Million SEK | 90.0% |
| Egetis Therapeutics AB (publ) | 760.2 Million SEK | 97.145% |
| Elicera Therapeutics AB (publ) | 30.17 Million SEK | 28.072% |
| ExpreS2ion Biotech Holding AB (publ) | 78.69 Million SEK | 72.42% |
| Fluicell AB (publ) | 9.34 Million SEK | -132.365% |
| Genovis AB (publ.) | 288.85 Million SEK | 92.487% |
| Guard Therapeutics International AB (publ) | 85.22 Million SEK | 74.535% |
| Hansa Biopharma AB (publ) | 1.01 Billion SEK | 97.868% |
| Infant Bacterial Therapeutics AB (publ) | 351.33 Million SEK | 93.823% |
| Mendus AB (publ) | 755.95 Million SEK | 97.129% |
| IRLAB Therapeutics AB (publ) | 177.12 Million SEK | 87.747% |
| Isofol Medical AB (publ) | 140.59 Million SEK | 84.564% |
| I-Tech AB | 152.44 Million SEK | 85.763% |
| Intervacc AB (publ) | 259.61 Million SEK | 91.64% |
| Kancera AB (publ) | 65.64 Million SEK | 66.938% |
| Karolinska Development AB (publ) | 1.25 Billion SEK | 98.275% |
| LIDDS AB (publ) | 17.65 Million SEK | -22.928% |
| Lipum AB (publ) | 12.11 Million SEK | -79.215% |
| Lipigon Pharmaceuticals AB (publ) | 33.6 Million SEK | 35.412% |
| Magle Chemoswed Holding AB (publ) | 278.74 Million SEK | 92.214% |
| Modus Therapeutics Holding AB (publ) | 20.04 Million SEK | -8.292% |
| Nanologica AB (publ) | 77.42 Million SEK | 71.971% |
| NextCell Pharma AB | 81.28 Million SEK | 73.301% |
| Oncopeptides AB (publ) | 238.37 Million SEK | 90.896% |
| OncoZenge AB (publ) | 20.34 Million SEK | -6.7% |
| Pila Pharma AB (publ) | 8.45 Million SEK | -156.687% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 41.95 Million SEK | 48.276% |
| Saniona AB (publ) | 64.14 Million SEK | 66.165% |
| Simris Alg AB (publ) | 174.55 Million SEK | 87.567% |
| Spago Nanomedical AB (publ) | 52.98 Million SEK | 59.04% |
| Sprint Bioscience AB (publ) | 62.37 Million SEK | 65.207% |
| SynAct Pharma AB | 228.01 Million SEK | 90.482% |
| Vicore Pharma Holding AB (publ) | 496.24 Million SEK | 95.627% |
| Xbrane Biopharma AB (publ) | 653.5 Million SEK | 96.679% |
| Xintela AB (publ) | 18.39 Million SEK | -17.982% |
| Xspray Pharma AB (publ) | 765.26 Million SEK | 97.164% |
| Ziccum AB (publ) | 14.97 Million SEK | -44.956% |